Outlook Therapeutics annual free cash flow
2015
2016
2017
2018
2019
Outlook Therapeutics Free Cash Flow (FCF) History (OTLK)
Outlook Therapeutics reported −$32.7M in free cash flow for fiscal 2019, an increase of $3.1M from the previous fiscal year, with a free cash flow margin of −401.75%.
View full Outlook Therapeutics company overviewOutlook Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2019 | 2019-09-30 | −$32.7M | $3.1M | — | −401.75% |
| 2018 | 2018-09-30 | −$35.8M | −$20.0M | — | −1160.16% |
| 2017 | 2017-09-30 | −$15.8M | $30.8M | — | −414.46% |
| 2016 | 2016-09-30 | −$46.6M | −$10.3M | — | −1563.34% |
| 2015 | 2015-09-30 | −$36.3M | — | — | −695.13% |
Outlook Therapeutics quarterly free cash flow
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2019 | 2019-09-30 | −$5.9M | $3.7M | — | −101.52% |
| Q3 2019 | 2019-06-30 | −$10.5M | −$1.8M | — | −1791.13% |
| Q2 2019 | 2019-03-31 | −$6.3M | $1.4M | — | −984.12% |
| Q1 2019 | 2018-12-31 | −$10.0M | −$271,588 | — | −938.35% |
| Q4 2018 | 2018-09-30 | −$9.7M | −$9.7M | — | −1251.08% |
| Q3 2018 | 2018-06-30 | −$8.7M | −$3.0M | — | −1127.54% |
| Q2 2018 | 2018-03-31 | −$7.7M | −$3.6M | — | −999.38% |
| Q1 2018 | 2017-12-31 | −$9.7M | −$3.8M | — | −1262.64% |
| Q4 2017 | 2017-09-30 | $55,874 | $10.8M | — | +1.93% |
| Q3 2017 | 2017-06-30 | −$5.7M | $10.8M | — | −1883.29% |
| Q2 2017 | 2017-03-31 | −$4.2M | $3.0M | — | −1370.32% |
| Q1 2017 | 2016-12-31 | −$6.0M | $6.4M | — | −1975.99% |
| Q4 2016 | 2016-09-30 | −$10.7M | $2.8M | — | −2161.82% |
| Q3 2016 | 2016-06-30 | −$16.5M | — | — | −3332.90% |
| Q2 2016 | 2016-03-31 | −$7.1M | — | — | −714.16% |
| Q1 2016 | 2015-12-31 | −$12.4M | — | — | −1244.00% |
| Q3 2015 | 2015-06-30 | −$13.5M | — | — | −1044.51% |
Outlook Therapeutics free cash flow growth trends
Outlook Therapeutics's latest reported quarter, Q4 2019, generated −$5.9M in free cash flow, an increase of $3.7M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Outlook Therapeutics filings at SEC.gov ↗